News and Announcements
Prescient Therapeutics Release Amended Appendix 3B – Rights Issue
- Published March 27, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Melbourne, Australia (27 March 2019): Prescient Therapeutics Limited (ACN 006 569 106) (ASX: PTX), a clinical stage oncology company, provides the attached amended Appendix 3B in relation to the Nonrenounceable Rights Issue to existing shareholders which was announced on 25 March 2019.
The pro-rata non-renounceable rights issue (Rights Issue) of ordinary shares in the Company (Shares) is being offered on a one-for-five basis at an issue price of $0.05 per Share (Offer Price), and one attaching new option (New Option) for every two New Shares subscribed for under the Rights Issue with an exercise price of $0.0625 per New Option and exercisable on 31 March 2023.
View the Amended Appendix 3B – Rights Issue
About Prescient Therapeutics (ASX: PTX, Prescient):
Prescient Therapeutics is developing drugs to treat a range of cancers with significant unmet need. Prescient has one of the deepest clinical pipelines on the ASX, with two drugs that turn off “master switches” that are known to drive cancer.
Exciting interim breast cancer data for PTX-200 has exhibited twice the effectiveness of standard therapy. A new transformative trial for PTX-100 will also soon commence.
Company Updates
The Index Approach in Early-Stage Venture Capital: Reconsidered
The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]
The Future Is Now: The Evolution of Dealflow with Wholesale Investor
If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]
Investability of a Startup: A Comprehensive Guide for Angels and High-Net Worth Investors
Venturing into the Startup Scene Let’s dive into the intriguing world of startups. It’s a thrilling ride, isn’t it? Like finding a pearl in an ocean, spotting a promising startup amidst a sea of businesses is no easy task. This guide aims to light the way, focusing on the “The Investability of a Startup: 7 […]
Backed By Leading Investment Groups and Family Offices
